| Name | Title | Contact Details |
|---|---|---|
David Sakadelis |
Chief Technology Officer | Profile |
Positive outcomes. Positive patient stories. These are our priorities at Paratek Pharmaceuticals. As a commercial-stage biopharmaceutical company, we develop transformative solutions for patients with infectious diseases and other difficult to treat conditions, and we believe that we have the right people, the right knowledge and the right drug to make a difference in patients` lives. Our Mission To create positive stories for patients, physicians and caregivers based on trust and integrity. To accomplish this, our employees work hard to turn everyday decisions into everyday triumphs that advance our technology and strengthen Paratek. Our Vision To be a leading independent biopharmaceutical company providing novel life-saving products for life-threatening diseases or other public health threats.
BCY LifeSciences Inc. is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
At Santen, we`re innovating therapies to improve the quality of life for patients worldwide. Our single focus in ophthalmology enables us to challenge unmet needs in the field—through passionate research, successful collaboration, and clarity of commitment. With over 120 years of investigative insight, Santen remains committed to the discovery, exploration, and development of ophthalmic therapies. Now, and into the future. As a global company, Santen is often expanding to accommodate new and evolving initiatives in ophthalmic research, regulatory management, production, marketing, or distribution. Our clinical development network now spans three continents, with centers in EMEA (Europe, the Middle East and Africa), Japan, and the United States.
Learn about who we are, our approach to scientific innovation, our areas of therapeutic focus, our products, commitments and more.
Kala Pharmaceuticals, Inc. (Kala) is a biopharmaceutical company focused on the development and commercialization of therapeutics using our proprietary nanoparticle-based Mucus Penetrating Particles, or MPP, technology, with an initial focus on the treatment of eye diseases.